The transformation to "intelligent manufacturing" has become the general trend of the development of the pharmaceutical industry!

There are a large number of pharmaceutical companies in China.
According to statistics, as of 2020, the number of pharmaceutical manufacturing companies in China has reached 7,665, an increase of 3.
8% year-on-year
.
It is worth noting that in recent years, with the advancement of policies such as consistency evaluation, medical insurance control fees, and centralized procurement, many pharmaceutical companies have begun to transform and upgrade from "manufacturing" to "intelligent manufacturing"
.
In this context, more and more companies have spent huge sums of money to build smart projects
.
The transformation to "intelligent manufacturing" has become the general trend of the development of the pharmaceutical industry (picture source: Pharmaceutical Network) Pharmaceutical companies are investing huge sums of money to build smart factories.
Construction has officially started
.
This project is an important manifestation of the Group's acceleration of the development of intelligence and high-end, and it is also a key project to enhance the international competitiveness of the company
.
It is estimated that the annual output of anti-tumor injections will reach 20 million bottles and the annual output of anti-tumor solid preparations will reach 100 million tablets, the output value will be more than 1.
5 billion yuan, and the annual profit will reach 300 million yuan
.
It is reported that the project will build 3 production lines for anti-tumor preparations, including non-terminal sterilization production lines for anti-tumor injections, terminal sterilization production lines for anti-tumor injections, and solid anti-tumor preparations production lines, all of which are in compliance with Chinese GMP, US FDA, European Union EU and other international standards.
First-class standards, and the use of world-class intelligent equipment and facilities
.
The project is expected to be put into production in the first half of 2023, which will greatly increase the Group's preparation production capacity, production technology level and product market competitiveness
.
For Hongdou Group's huge investment in building a smart factory project for high-end complex anti-tumor preparations, the industry believes that this is mainly because the pharmaceutical industry is facing the challenge of large-scale production.
Traditional production methods can no longer meet the production needs, and more and more pharmaceutical companies The demand for intelligence has begun to reach a new level
.
At present, in addition to the Hongdou Group is accelerating the creation of high-end smart domestic products, many companies are also vigorously deploying smart factory projects
.
For example, Qilu Pharmaceutical is accelerating the construction of high-end intelligent processing and manufacturing center projects this year. .
It is understood that the project is expected to have a total investment of nearly 700 million yuan.
After completion, it is expected to become a domestically automated and intelligent pharmaceutical production line that will help pharmaceutical companies achieve stable and over-production and improve production efficiency
.
Domestic large-scale pharmaceutical machinery companies are vigorously promoting intelligent manufacturing.
In the context of the upgrading of pharmaceutical user needs, the rapid development of intelligent manufacturing, and the rising raw material and labor costs of the pharmaceutical equipment industry, the transformation from "manufacturing" to "intelligent manufacturing" has also become a medicine.
The general trend of the machine industry
.
According to the author's understanding, as a pharmaceutical equipment industry closely related to the pharmaceutical industry, pharmaceutical companies are actively promoting the intelligent manufacturing of high-end pharmaceutical preparations at the moment
.
For example, the Canaan Intelligent Medical Equipment Manufacturing Project with a total investment of 1 billion yuan by Canaan Science and Technology has now all three standardized production workshops completed, and the rest are progressing in an orderly manner.
It is planned to be completed by the end of 2021 and completed in 2023
.
The project is aimed at the core areas of the health industry such as granulation line equipment and solid preparation equipment.
After it is put into production, it can achieve an annual output of 4,000 sets of high-end pharmaceutical equipment, and the company's output value will increase by 5 times
.
It is worth mentioning that in the next step, Canaan Technology will also make efforts in digital twin technology, intelligent production, digital management, networked collaboration, personalized customization, etc.
, to create a two-way "factory of the future".
At the same time, the company will also strive to improve Intelligent and complete line engineering design capabilities provide users with more high value-added services
.
In addition, Chutian Technology has also actively promoted the development of pharmaceutical intelligent manufacturing in recent years
.
On April 28, 2020, the fourth phase of the project has officially started construction.
The project includes Chutian Science and Technology Innovation Center Building, Talent Center Building, Central Workshop, Intelligent Backpack Workshop, Intelligent Chinese Medicine Workshop and other R&D, manufacturing and management units Modern building
.
Among them, the smart packaging workshop has been put into production, and the entire project is scheduled to be completed in the first half of 2022
.
Conclusion In general, as the development of smart manufacturing has gradually become a trend, the smart manufacturing projects of domestic pharmaceutical equipment companies have also begun to continue to advance
.
The industry believes that in the future, with the unremitting efforts of many pharmaceutical machinery companies, the overall intelligence level of China's pharmaceutical equipment will be further improved, promote the intelligent transformation and upgrading of the pharmaceutical industry, and provide better guarantees for the quality and safety of pharmaceutical production
.